Molecular basis of the potential of mesalazine to prevent colorectal cancer

作     者：Carmine Stolfi Roberto Pellegrini Eleonora Franzè Francesco Pallone Giovanni Monteleone 

作者机构：Department of Internal MedicineUniversity Tor Vergata of RomeRome 00133Italy 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2008年第14卷第28期

页      面：4434-4439页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Chemoprevention Colorectal cancer Cyclooxygenase-2 Epidermal growth factor receptor Inflammatory bowel disease Mesalazine Wnt/β-catenin 

摘      要：Patients with ulcerative colitis (UC) and Crohn s disease (CD) are at increased risk for developing colorectal cancer (CRC), and this is believed to be a result of chronic inflammation. Although conclusive evidence is still missing, both epidemiological and experimental observations suggest that certain drugs used to treat inflammation, such as mesalazine, can reduce the incidence of colitis-associated CRC. Therefore, in recent years, several studies have been conducted to dissect the mechanisms by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular mechanisms that underlie the antineoplastic action of mesalazine.